171 related articles for article (PubMed ID: 35508598)
1. Plasma lncRNA LOC338963 and mRNA AP3B2 are upregulated in paraneoplastic Lambert-Eaton myasthenic syndrome.
Yang F; Jing F; Li Y; Kong S; Zhang S; Huo Y; Huang X; Yu S
Muscle Nerve; 2022 Aug; 66(2):216-222. PubMed ID: 35508598
[TBL] [Abstract][Full Text] [Related]
2. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer.
Liu Y; Xi J; Zhou L; Wu H; Yue D; Zhu W; Lin J; Lu J; Zhao C; Qiao K
J Clin Neurosci; 2019 Jul; 65():41-45. PubMed ID: 31072737
[TBL] [Abstract][Full Text] [Related]
4. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B; Eymard B; Datt J; Mantegazza R
J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
[TBL] [Abstract][Full Text] [Related]
5. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.
Titulaer MJ; Klooster R; Potman M; Sabater L; Graus F; Hegeman IM; Thijssen PE; Wirtz PW; Twijnstra A; Smitt PA; van der Maarel SM; Verschuuren JJ
J Clin Oncol; 2009 Sep; 27(26):4260-7. PubMed ID: 19667272
[TBL] [Abstract][Full Text] [Related]
6. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
[TBL] [Abstract][Full Text] [Related]
7. Relapse of both small cell lung cancer and Lambert-Eaton myasthenic syndrome after a 13-year disease-free survival period.
Asano F; Watanabe K; Shinkai M; Tei Y; Mishina K; Tanabe M; Ishii H; Shinoda M; Shimokawaji T; Kudo M; Kaneko T
Chin J Cancer; 2016 Jul; 35(1):63. PubMed ID: 27370896
[TBL] [Abstract][Full Text] [Related]
8. SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma.
Lipka AF; Verschuuren JJ; Titulaer MJ
Ann N Y Acad Sci; 2012 Dec; 1275():70-7. PubMed ID: 23278580
[TBL] [Abstract][Full Text] [Related]
9. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
Hülsbrink R; Hashemolhosseini S
Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
[TBL] [Abstract][Full Text] [Related]
10. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
Kitanosono H; Shiraishi H; Motomura M
Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
[TBL] [Abstract][Full Text] [Related]
11. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome.
Wirtz PW; Willcox N; van der Slik AR; Lang B; Maddison P; Koeleman BP; Giphart MJ; Wintzen AR; Roep BO; Verschuuren JJ
J Neuroimmunol; 2005 Feb; 159(1-2):230-7. PubMed ID: 15652424
[TBL] [Abstract][Full Text] [Related]
12. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
Pellkofer HL; Armbruster L; Krumbholz M; Titulaer MJ; Verschuuren JJ; Schumm F; Voltz R
J Neuroimmunol; 2008 Nov; 204(1-2):136-9. PubMed ID: 18809213
[TBL] [Abstract][Full Text] [Related]
13. [Lambert-Eaton myasthenic syndrome].
Motomura M; Fukuda T
Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145
[TBL] [Abstract][Full Text] [Related]
14. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
Honnorat J
Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic Lambert-Eaton myasthenic syndrome: a diagnostic challenge.
Viveiros L; Martins SR; Pires SX; Neves J
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36707096
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.
Lipka AF; Boldingh MI; van Zwet EW; Schreurs MWJ; Kuks JBM; Tallaksen CM; Titulaer MJ; Verschuuren JJGM
Neurology; 2020 Feb; 94(5):e511-e520. PubMed ID: 31831596
[TBL] [Abstract][Full Text] [Related]
17. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.
Wirtz PW; Nijnuis MG; Sotodeh M; Willems LN; Brahim JJ; Putter H; Wintzen AR; Verschuuren JJ;
J Neurol; 2003 Jun; 250(6):698-701. PubMed ID: 12796832
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.
Maddison P; Gozzard P; Grainge MJ; Lang B
Neurology; 2017 Apr; 88(14):1334-1339. PubMed ID: 28251917
[TBL] [Abstract][Full Text] [Related]
19. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
Vincent A; Lang B; Newsom-Davis J
Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
[TBL] [Abstract][Full Text] [Related]
20. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.
Payne M; Bradbury P; Lang B; Vincent A; Han C; Newsom-Davis J; Talbot D
J Thorac Oncol; 2010 Jan; 5(1):34-8. PubMed ID: 19934775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
